2026-01-28 – Press Releases – www.prnewswire.com
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ — Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. (“Sciwind”), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature…
